Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases

Fasting and postprandial hypertriglyceridemia is a risk factor for atherosclerotic cardiovascular diseases (ASCVD). Fibrates have been used to treat dyslipidemia, particularly hypertriglyceridemia, and low HDL-cholesterol (HDL-C). However, conventional fibrates have low selectivity for peroxisome pr...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Atheroscler Thromb
Hlavní autoři: Yamashita, Shizuya, Masuda, Daisaku, Matsuzawa, Yuji
Médium: Artigo
Jazyk:Inglês
Vydáno: Japan Atherosclerosis Society 2019
Témata:
Review
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6514171/
https://ncbi.nlm.nih.gov/pubmed/30930344
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5551/jat.48918
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky